AIM Vaccine's Iteratively Upgraded Diploid Rabies Vaccine Approved for Clinical Trials, Showing Significantly Higher Efficacy than Marketed Diploid Rabies Vaccines

March 10, 2025 11:00 AM AEDT | By Cision

Google News:

AIM Vaccine's Iteratively Upgraded Diploid Rabies Vaccine Approved for Clinical Trials, Showing Significantly Higher Efficacy than Marketed Diploid Rabies Vaccines — Image source: Kalkine Media

Recent News

'Journey Through Time' is an enlightening exploration of RCIA by Laure...

“Life of Abuse to Success: A Child’s Story” is a poignant memoir of re...

CNH Expands Connectivity Solutions With SpaceX’s Starlink

Between Hunger and Hope: a Story of Humanity in the Heart of Gaza

HONG KONG, March 10, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 9, 2025, the company's research and development of a diploid rabies vaccine has recently received the Clinical Trial Approval Notice from the National Medical Products Administration. This product is an upgraded version of the diploid rabies vaccine, featuring significantly high efficacy, marking a major iterative upgrade in the global rabies vaccine technology field. Animal trials have shown that the vaccine generates antibodies that provide a high level of protection, with efficacy significantly surpassing that of already marketed diploid rabies vaccines under the same dosage conditions.

This vaccine has successfully overcome the technical bottlenecks of traditional processes, which are characterized by low virus titer and low yield. Optimizations and innovations have been made in the purification process, resulting in significant improvements in product quality and safety. It can be administered using a five-injection method, a simplified four-injection method, or a 2-1-1 four-injection method, offering more flexibility and convenience.

Since February, AIM Vaccine has made several breakthrough advancements that highlight its innovative capabilities and global strategy. Its mRNA RSV (Respiratory Syncytial Virus) vaccine has received clinical approval in the U.S., and the company announced a comprehensive deployment of the DeepSeek large model, realizing a strategic upgrade to an "AI + Smart Vaccine Enterprise."

In the context of major global investment banks raising target prices for Chinese assets, biotech stocks with high technological innovation content are expected to encounter significant opportunities. China Galaxy International Securities^[1] believes that the pharmaceutical sector will undergo a recovery, and structural opportunities still exist. From the perspective of short-term and medium-to-long-term growth certainty, it is optimistic about the innovative pharmaceutical supply chain, international expansion, and leading companies in niche sectors.

Fosun International Securities^[2] previously pointed out that AIM's innovative products are driving a revaluation of its value. Considering AIM Vaccine's strong R&D capabilities, technological leadership, and international market expansion potential, it has assigned a "Buy" rating with a target price of HKD 11.

Note 1: http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=GLH1848484L&catg=1&source=GLH

Note 2: http://www.aastocks.com/tc/stocks/news/glh-news/GLH1832345L/1

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.